| 1 |
Lui YY, Chik KW, Chiu RW, et al. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation[J]. Clin Chem, 2002, 48(3): 421-427.
|
| 2 |
Elshimali YI, Khaddour H, Sarkissyan M, et al. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients[J]. Int J Mol Sci, 2013, 14(9): 18925-18958.
|
| 3 |
Lam WKJ, Gai W, Sun K, et al. DNA of erythroid origin is present in human plasma and informs the types of anemia[J]. Clin Chem, 2017, 63(10): 1614-1623.
|
| 4 |
Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids-a promising, non-invasive tool for early detection of several human diseases[J]. FEBS Lett, 2007, 581(5): 795-799.
|
| 5 |
Anker P, Stroun M, Maurice PA. Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system[J]. Cancer Res, 1975, 35(9): 2375-2382.
|
| 6 |
Stroun M, Anker P. Nucleic acids spontaneously released by living frog auricles[J]. Biochem J, 1972, 128(3): 100p-101p.
|
| 7 |
Snyder MW, Kircher M, Hill AJ, et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin[J]. Cell, 2016, 164(1-2): 57-68.
|
| 8 |
Kustanovich A, Schwartz R, Peretz T, et al. Life and death of circulating cell-free DNA[J]. Cancer Biol Ther, 2019, 20(8): 1057-1067.
|
| 9 |
Stroun M, Maurice P, Vasioukhin V, et al. The origin and mechanism of circulating DNA[J]. Ann N Y Acad Sci, 2000, 906(1): 161-168.
|
| 10 |
Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells[J]. Cancer Res, 2001, 61(4): 1659-1665.
|
| 11 |
Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey[J]. Biochim Biophys Acta, 2007, 1775(1): 181-232.
|
| 12 |
Cicchillitti L, Corrado G, De Angeli M, et al. Circulating cell-free DNA content as blood based biomarker in endometrial cancer[J]. Oncotarget, 2017, 8(70): 115230-115243.
|
| 13 |
Beiter T, Fragasso A, Hudemann J, et al. Short-term treadmill running as a model for studying cell-free DNA kinetics in vivo[J]. Clin Chem, 2011, 57(4): 633-636.
|
| 14 |
García Moreira V, de la Cera Martínez T, Gago González E, et al. Increase in and clearance of cell-free plasma DNA in hemodialysis quantified by real-time PCR[J]. Clin Chem Lab Med, 2006, 44(12): 1410-1415.
|
| 15 |
Celec P, Vlková B, Lauková L, et al. Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases[J]. Expert Rev Mol Med, 2018, 20: e1.
|
| 16 |
Gauthier VJ, Tyler LN, Mannik M. Blood clearance kinetics and liver uptake of mononucleosomes in mice[J]. J Immunol, 1996, 156(3): 1151-1156.
|
| 17 |
Du Clos TW, Volzer MA, Hahn FF, et al. Chromatin clearance in C57Bl/10 mice: interaction with heparan sulphate proteoglycans and receptors on kupffer cells[J]. Clin Exp Immunol, 1999, 117(2): 403-411.
|
| 18 |
Oellerich M, Sherwood K, Keown P, et al. Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury[J]. Nat Rev Nephrol, 2021, 17(9): 591-603.
|
| 19 |
Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy[J]. Cancer Res, 1977, 37(3): 646-650.
|
| 20 |
Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer[J]. Clinical Chemistry, 2015, 61(1): 112-123.
|
| 21 |
Ulrich BC, Paweletz CP. Cell-free DNA in oncology: gearing up for clinic[J]. Ann Lab Med, 2018, 38(1): 1-8.
|
| 22 |
Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum[J]. Lancet, 1997, 350(9076): 485-487.
|
| 23 |
Lo YM, Tein MS, Pang CC, et al. Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients[J]. Lancet, 1998, 351(9112): 1329-1330.
|
| 24 |
Snyder TM, Khush KK, Valantine HA, et al. Universal noninvasive detection of solid organ transplant rejection[J]. Proc Natl Acad Sci U S A, 2011, 108(15): 6229-6234.
|
| 25 |
Gielis EM, Ledeganck KJ, De Winter BY, et al. Cell-free DNA: an upcoming biomarker in transplantation[J]. Am J Transplant, 2015, 15(10): 2541-2551.
|
| 26 |
Beck J, Oellerich M, Schütz E. A universal droplet digital PCR approach for monitoring of graft health after transplantation using a preselected SNP set[J]. Methods Mol Biol, 2018, 1768: 335-348.
|
| 27 |
Dauber EM, Kollmann D, Kozakowski N, et al. Quantitative PCR of INDELs to measure donor-derived cell-free DNA-a potential method to detect acute rejection in kidney transplantation: a pilot study[J]. Transpl Int, 2020, 33(3): 298-309.
|
| 28 |
Grskovic M, Hiller DJ, Eubank LA, et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients[J]. J Mol Diagn, 2016, 18(6): 890-902.
|
| 29 |
Altuğ Y, Liang N, Ram R, et al. Analytical validation of a single-nucleotide polymorphism-based donor-derived cell-free DNA assay for detecting rejection in kidney transplant patients[J]. Transplantation, 2019, 103(12): 2657-2665.
|
| 30 |
Zhou Y, Yang G, Liu H, et al. A Noninvasive and donor-independent method simultaneously monitors rejection and infection in patients with organ transplant[J]. Transplant Proc, 2019, 51(6): 1699-1705.
|
| 31 |
De Vlaminck I, Valantine HA, Snyder TM, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection[J]. Sci Transl Med, 2014, 6(241): 241ra77.
|
| 32 |
Bloom RD, Bromberg JS, Poggio ED, et al. Cell-free DNA and active rejection in kidney allografts[J]. J Am Soc Nephrol, 2017, 28(7): 2221-2232.
|
| 33 |
Halloran PF, Reeve J, Madill-Thomsen KS, et al. The Trifecta study: comparing plasma levels of donor-derived cell-free DNA with the molecular phenotype of kidney transplant biopsies[J]. J Am Soc Nephrol, 2022, 33(2): 387-400.
|
| 34 |
Levitsky J, Kandpal M, Guo K, et al. Donor-derived cell-free DNA levels predict graft injury in liver transplant recipients[J]. Am J Transplant, 2022, 22(2): 532-540.
|
| 35 |
Levitsky J, Kandpal M, Guo K, et al. Donor-derived cell-free DNA kinetics post-kidney transplant biopsy[J]. Transplant Direct, 2021, 7(6): e703.
|
| 36 |
Shen J, Guo L, Yan P, et al. Prognostic value of the donor-derived cell-free DNA assay in acute renal rejection therapy: a prospective cohort study[J]. Clinical Transplantation, 2020, 34(10): e14053.
|
| 37 |
Lee TH, Montalvo L, Chrebtow V, et al. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma[J]. Transfusion, 2001, 41(2): 276-282.
|
| 38 |
Jung M, Klotzek S, Lewandowski M, et al. Changes in concentration of DNA in serum and plasma during storage of blood samples[J]. Clin Chem, 2003, 49(6 Pt 1): 1028-1029.
|
| 39 |
Parpart-Li S, Bartlett B, Popoli M, et al. The Effect of preservative and temperature on the analysis of circulating tumor DNA[J]. Clin Cancer Res, 2017, 23(10): 2471-2477.
|
| 40 |
Zhou Q, Liu F, Guo L, et al. A novel urine cell-free DNA preservation solution and its application in kidney transplantation[J]. Nephrology (Carlton), 2021, 26(8): 684-691.
|
| 41 |
Bu L, Gupta G, Pai A, et al. Clinical outcomes from the assessing donor-derived cell-free DNA monitoring insights of kidney allografts with longitudinal surveillance (ADMIRAL) study[J]. Kidney Int, 2022, 101(4): 793-803.
|
| 42 |
Sun K, Jiang P, Chan KC, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments[J]. Proc Natl Acad Sci U S A, 2015, 112(40): E5503-E5512.
|
| 43 |
Oellerich M, Shipkova M, Asendorf T, et al. Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: results from a prospective observational study[J]. Am J Transplant, 2019, 19(11): 3087-3099.
|
| 44 |
Whitlam JB, Ling L, Skene A, et al. Diagnostic application of kidney allograft-derived absolute cell-free DNA levels during transplant dysfunction[J]. Am J Transplant, 2019, 19(4): 1037-1049.
|
| 45 |
Shen J, Zhou Y, Chen Y, et al. Dynamics of early post-operative plasma ddcfDNA levels in kidney transplantation: a single-center pilot study[J]. Transpl Int, 2019, 32(2): 184-192.
|
| 46 |
Zhang J, Tong KL, Li PK, et al. Presence of donor- and recipient-derived DNA in cell-free urine samples of renal transplantation recipients: urinary DNA chimerism[J]. Clin Chem, 1999, 45(10): 1741-1746.
|
| 47 |
Huang E, Sethi S, Peng A, et al. Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipients[J]. Am J Transplant, 2019, 19(6): 1663-1670.
|
| 48 |
Zhong XY, Hahn D, Troeger C, et al. Cell-free DNA in urine: a marker for kidney graft rejection, but not for prenatal diagnosis？[J]. Ann N Y Acad Sci, 2001, 945: 250-257.
|
| 49 |
Sigdel TK, Vitalone MJ, Tran TQ, et al. A rapid noninvasive assay for the detection of renal transplant injury[J]. Transplantation, 2013, 96(1): 97-101.
|
| 50 |
Gielis EM, Ledeganck KJ, Dendooven A, et al. The use of plasma donor-derived, cell-free DNA to monitor acute rejection after kidney transplantation[J]. Nephrol Dial Transplant, 2019, 35(4): 714-721.
|
| 51 |
Parajuli S, Reville PK, Ellis TM, et al. Utility of protocol kidney biopsies for de novo donor-specific antibodies[J]. Am J Transplant, 2017, 17(12): 3210-3218.
|
| 52 |
Schinstock CA, Cosio F, Cheungpasitporn W, et al. The value of protocol biopsies to identify patients with de novo donor-specific antibody at high risk for allograft loss[J]. Am J Transplant, 2017, 17(6): 1574-1584.
|
| 53 |
Cheng D, Liu F, Xie K, et al. Donor-derived cell-free DNA: an independent biomarker in kidney transplant patients with antibody-mediated rejection[J]. Transpl Immunol, 2021, 69: 101404.
|
| 54 |
Stites E, Kumar D, Olaitan O, et al. High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury[J]. Am J Transplant, 2020, 20(9): 2491-2498.
|
| 55 |
Zhang H, Zheng C, Li X, et al. Diagnostic performance of donor-derived plasma cell-free DNA fraction for antibody-mediated rejection in post renal transplant recipients: a prospective observational study[J]. Front Immunol, 2020, 11: 342.
|
| 56 |
Jordan SC, Bunnapradist S, Bromberg JS, et al. Donor-derived cell-free DNA identifies antibody-mediated rejection in donor specific antibody positive kidney transplant recipients[J]. Transplant Direct, 2018, 4(9): e379.
|
| 57 |
Obrişcă B, Butiu M, Sibulesky L, et al. Combining donor-derived cell-free DNA and donor specific antibody testing as non-invasive biomarkers for rejection in kidney transplantation[J]. Sci Rep, 2022, 12(1): 15061.
|
| 58 |
Mayer KA, Doberer K, Tillgren A, et al. Diagnostic value of donor-derived cell-free DNA to predict antibody-mediated rejection in donor-specific antibody-positive renal allograft recipients[J]. Transpl Int, 2021, 34(9): 1689-1702.
|
| 59 |
Loupy A, Vernerey D, Tinel C, et al. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts[J]. J Am Soc Nephrol, 2015, 26(7): 1721-1731.
|
| 60 |
Wijtvliet VPWM, Plaeke P, Abrams S, et al. Donor-derived cell-free DNA as a biomarker for rejection after kidney transplantation: a systematic review and meta-analysis[J]. Transpl Int, 2020, 33(12): 1626-1642.
|
| 61 |
Shen J, Guo L, Lei W, et al. Urinary donor-derived cell-free DNA as a non-invasive biomarker for BK polyomavirus-associated nephropathy[J]. J Zhejiang Univ Sci B, 2021, 22(11): 917-928.
|
| 62 |
Cheng D, Feng L, Liu H, et al. Simultaneously detection of ddcfdna in plasma and urine assist to determine the type of rejection in renal transplant patients[J]. Transplantation, 104(S3)：S40-S40.
|
| 63 |
Guo L, Shen J, Lei W, et al. Plasma donor-derived cell-free DNA levels are associated with the inflammatory burden and macrophage extracellular trap activity in renal allografts[J]. Front Immunol, 2022, 13: 796326.
|
| 64 |
Halloran PF, Reeve J, Madill-Thomsen KS, et al. Combining donor-derived cell-free DNA fraction and quantity to detect kidney transplant rejection using molecular diagnoses and histology as confirmation[J]. Transplantation, 2022.
|
| 65 |
Halloran PF, Reeve J, Madill-Thomsen KS, et al. Antibody-mediated rejection without detectable donor-specific antibody releases donor-derived cell-free DNA: results from the Trifecta study[J]. Transplantation, 2022.
|
| 66 |
Huang E, Gillespie M, Ammerman N, et al. Donor-derived cell-free DNA combined with histology improves prediction of estimated glomerular filtration rate over time in kidney transplant recipients compared with histology alone[J]. Transplantation Direct, 2020, 6(8): e580.
|
| 67 |
Gielis EM, Beirnaert C, Dendooven A, et al. Plasma donor-derived cell-free DNA kinetics after kidney transplantation using a single tube multiplex PCR assay[J]. PLoS One, 2018, 13(12): e0208207.
|
| 68 |
Hinojosa RJ, Chaffin K, Gillespie M, et al. Donor-derived cell-free DNA may confirm real-time response to treatment of acute rejection in renal transplant recipients[J]. Transplantation, 2019, 103(4): e61.
|
| 69 |
Pai A, Swan JT, Wojciechowski D, et al. Clinical rationale for a routine testing schedule using donor-derived cell-free DNA after kidney transplantation[J]. Ann Transplant, 2021, 26: e932249.
|
| 70 |
Wolf-Doty TK, Mannon RB, Poggio ED, et al. Dynamic response of donor-derived cell-free DNA following treatment of acute rejection in kidney allografts[J]. Kidney360, 2021, 2(4): 729-736.
|
| 71 |
Puliyanda DP, Swinford R, Pizzo H, et al. Donor-derived cell-free DNA (dd-cfDNA) for detection of allograft rejection in pediatric kidney transplants[J]. Pediatr Transplant, 2021, 25(2): e13850.
|
| 72 |
Nie W, Su X, Liu L, et al. Dynamics of donor-derived cell-free DNA at the early phase after pediatric kidney transplantation: a prospective cohort study[J]. Front Med (Lausanne), 2022, 8: 814517.
|
| 73 |
Steggerda JA, Pizzo H, Garrison J, et al. Use of a donor-derived cell-free DNA assay to monitor treatment response in pediatric renal transplant recipients with allograft rejection[J]. P Pediatr Transplant, 2022, 26(4): e14258.
|
| 74 |
Mehta SG, Chang JH, Alhamad T, et al. Repeat kidney transplant recipients with active rejection have elevated donor-derived cell-free DNA[J]. Am J Transplant, 2019, 19(5): 1597-1598.
|
| 75 |
Sureshkumar KK, Lyons S, Chopra B. Impact of kidney transplant type and previous transplant on baseline donor-derived cell free DNA[J]. Transpl Int, 2020, 33(10): 1324-1325.
|
| 76 |
Chen XT, Chen WF, Li J, et al. Urine donor-derived cell-free DNA helps discriminate BK polyomavirus-associated nephropathy in kidney transplant recipients with BK polyomavirus infection[J]. Front Immunol, 2020, 11: 1763.
|
| 77 |
Kant S, Bromberg J, Haas M, et al. Donor-derived cell-free DNA and the prediction of BK virus-associated nephropathy[J]. Transplant Direct, 2020, 6(11): e622.
|
| 78 |
Chen XT, Qiu J, Wu ZX, et al. Using both plasma and urine donor-derived cell-free DNA to identify various renal allograft injuries[J]. Clin Chem, 2022, 68(6): 814-825.
|
| 79 |
Urosevic N, Merritt AJ, Inglis TJJ. Plasma cfDNA predictors of established bacteraemic infection[J]. Access Microbiol, 2022, 4(6): acmi000373.
|
| 80 |
Waldvogel Abramowski S, Tirefort D, Lau P, et al. Cell-free nucleic acids are present in blood products and regulate genes of innate immune response[J]. Transfusion, 2018, 58(7): 1671-1681.
|
| 81 |
Tug S, Helmig S, Deichmann ER, et al. Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage[J]. Exerc Immunol Rev, 2015, 21: 164-173.
|
| 82 |
Mondelo-Macía P, Castro-Santos P, Castillo-García A, et al. Circulating free DNA and its emerging role in autoimmune diseases[J]. J Pers Med, 2021, 11(2): 151.
|
| 83 |
Truszewska A, Foroncewicz B, Pczek L. The role and diagnostic value of cell-free DNA in systemic lupus erythematosus[J]. Clin Exp Rheumatol, 2017, 35(2): 330-336.
|
| 84 |
Sureshkumar KK, Aramada HR, Chopra B. Impact of body mass index and recipient age on baseline donor-derived cell free DNA (dd-cfDNA) in kidney transplant recipients[J]. Clin Transplant, 2020, 34(12): e14101.
|
| 85 |
Bianchi DW. Cherchez la femme: maternal incidental findings can explain discordant prenatal cell-free DNA sequencing results[J]. Genet Med, 2018, 20(9): 910-917.
|
| 86 |
Yan L, Chen Y, Zhou J, et al. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma[J]. Int J Infect Dis, 2018, 67: 92-97.
|
| 87 |
Anand S, Lopez-Verdugo F, Sanchez-Garcia J, et al. Longitudinal variance of donor-derived cell-free DNA (dd-cfDNA) in stable kidney transplant (KTx) patients are influenced by donor/recipient variables[J]. Clin Transplant, 2021, 35(9): e14395.
|